What's Happening?
Health tech startup Forus, previously known as Tandem, has announced a partnership with the American Gastroenterological Association (AGA) to improve medication access for patients with digestive diseases. Forus utilizes an artificial intelligence-powered
network to streamline the prescription process, connecting doctors, pharmacies, payers, and biopharma. This technology automates prior authorizations, appeals, financial assistance, and pharmacy routing, aiming to reduce the administrative burden on healthcare providers and patients. The partnership with AGA is designed to leverage Forus's platform to address delays and denials in medication access, particularly for patients with complex conditions such as autoimmune diseases, COPD, psoriasis, and cancers. The collaboration will focus on analyzing guideline-based care to identify gaps in treatment access and improve adherence to best-practice medicine.
Why It's Important?
The partnership between Forus and AGA is significant as it addresses a critical issue in healthcare: the accessibility and affordability of medications for patients with complex and costly conditions. By automating the prescription process, Forus aims to reduce the time and effort required for patients to receive necessary medications, potentially improving health outcomes and reducing healthcare costs. This initiative is particularly important for patients with digestive diseases, who often face significant barriers to accessing prescribed treatments. The collaboration also highlights the growing role of artificial intelligence in healthcare, offering a model for how technology can be used to streamline processes and improve patient care.
What's Next?
As the partnership develops, Forus and AGA plan to analyze the impact of guideline-based care on treatment access and identify areas where patients are not receiving optimal therapies. Insights from Forus's platform will help AGA target efforts to improve access and adherence to best-practice medicine. The collaboration is expected to grow over time, with joint findings and resources for the GI community anticipated. Additionally, Forus's recent $160 million funding round will support the expansion of its AI-powered prescription processing platform, potentially leading to further partnerships and innovations in medication access.
